Acute Pulmonary Thromboembolism (PTE) - Detailed Clinical Approach

STEP 1 - Immediate Stabilization (First 30 Minutes)

• Supplemental O2 to keep SpO2 >94%; use high-flow mask if needed
• Avoid aggressive positive pressure ventilation - high intrathoracic pressure further reduces RV preload and can cause hemodynamic collapse
• Establish 2 large-bore IV access lines
• Continuous cardiac monitoring + pulse oximetry + blood pressure monitoring
• 12-lead ECG immediately

• Sinus tachycardia (most common)
• S1Q3T3 pattern (right heart strain)
• New RBBB
• T-wave inversions V1-V4
• Atrial fibrillation

STEP 2 - Risk Stratification (Determines Urgency of Each Step)

Your patient fits intermediate-risk if hemodynamically stable with RV strain findings, or high-risk if already in shock. The plan to "thrombolyse only if hemodynamic instability" is standard for intermediate-risk PE.

• Fuster & Hurst's The Heart 15e: "The risk-stratification terminology has evolved... the term 'high-risk' (rather than 'massive') is preferred" and "RV dysfunction and increased levels of troponin and/or natriuretic peptides... may be associated with... cardiovascular collapse and death."

STEP 3 - Urgent Investigations

• CBC, PT/INR, aPTT, anti-Xa level (baseline before heparin)
• ABG (hypoxia, hypocapnia, increased A-a gradient)
• D-dimer (elevated but non-specific; useful if diagnosis still in question)
• Troponin I/T (RV injury marker - prognostic)
• BNP/NT-proBNP (RV pressure overload marker - prognostic)
• Renal function (CrCl affects anticoagulant choice)
• Serum lactate (elevated = poor prognosis even if normotensive)
• Blood group and screen

• CTPA - gold standard for confirmed PTE; also provides clot burden, RV:LV ratio
• CXR - may show Westermark sign, Hampton's hump, pleural effusion, or be normal
• Bedside point-of-care echo/ECHO - assess RV size and function, McConnell sign, free-floating thrombus, RV hypokinesis; essential if CTPA not immediately available or patient too unstable

• RV:LV ratio >0.9 on CT
• RV dilation/hypokinesis on echo
• Elevated troponin
• Elevated BNP
• McConnell sign (free wall hypokinesis with preserved apex)
• Raised lactate

STEP 4 - ANTICOAGULATION (Start Now)

• Bolus: 80 units/kg IV (some protocols use 30 units/kg for PE)
• Infusion: 18 units/kg/hr continuous IV infusion
• Target aPTT: 1.5-2.5x the upper limit of normal (corresponding to anti-Xa 0.3-0.7 U/mL)
• Check aPTT at 6 hours; adjust per weight-based nomogram
• Monitor platelet count after 5 days (heparin-induced thrombocytopenia risk)

Murray & Nadel's Respiratory Medicine: "Prompt initiation of continuous intravenous UFH according to dosing protocols... reduces the risk of recurrent VTE dramatically. Hull and colleagues reported a 15-fold increase in the rate of recurrent VTE in patients who did not have a therapeutic anticoagulant effect within 24 hours."

Tintinalli's Emergency Medicine: "Unfractionated heparin 30 units/kg IV bolus followed by 18 units/kg per h continuous IV infusion, with aPTT checked after 6h and infusion adjusted to maintain anti-Xa activity 0.3-0.7 nmol/L."

• Can be rapidly reversed/stopped before thrombolysis
• Better titrated in hemodynamically unstable patients
• Preferred in renal impairment (LMWH accumulates if CrCl <30)
• Effect monitorable in real-time (aPTT, anti-Xa)

• Enoxaparin 1 mg/kg SC every 12 hours OR 1.5 mg/kg SC once daily

STEP 5 - MONITORING FOR HEMODYNAMIC INSTABILITY

• SBP <90 mmHg for >15 minutes not attributable to hypovolemia/arrhythmia/sepsis
• SBP drop >40 mmHg from baseline
• Need for vasopressors to maintain SBP >90
• Cardiac arrest due to PE
• Clinical signs of shock: cold extremities, mottled skin, altered mentation, oliguria, rising lactate

• HR, BP (non-invasive every 15 min in first 2 hours)
• SpO2 continuous
• Urine output hourly
• Repeat troponin at 4-6 hours
• Repeat bedside echo if clinical deterioration

STEP 6 - THROMBOLYSIS (Only if Hemodynamic Instability Develops)

• Any of the hemodynamic instability criteria above are met despite adequate anticoagulation

• Miller's Anesthesia 10e: "Thrombolytics are indicated in the setting of hemodynamic instability due to acute pulmonary embolus. A meta-analysis in patients with massive pulmonary embolism found that systemic thrombolytic therapy decreased the composite endpoint of death and recurrent thromboembolism (9.4% vs. 19%, OR 0.45, 95% CI 0.22-0.92)."

1. Stop UFH infusion immediately (no reversal agent needed - just stop)
2. Confirm PE diagnosis
3. Obtain consent if possible (life-threatening emergency may preclude this)
4. Have resuscitation team at bedside

• Do NOT restart anticoagulation for 2 hours after alteplase completion
• Restart UFH infusion (without bolus) when aPTT <80 seconds
• Monitor closely for bleeding: neurological changes, access site bleeding, hemoptysis

STEP 7 - ESCALATION OPTIONS (If Thrombolysis Fails or is Contraindicated)

• Surgical embolectomy - if systemic thrombolysis fails or is absolutely contraindicated; requires cardiac surgery team
• Catheter-directed thrombolysis (CDT) - low-dose local tPA via catheter; reduces bleeding risk vs systemic; consider for intermediate-high risk PE or where systemic thrombolysis contraindicated
• Catheter embolectomy / fragmentation - mechanical disruption; considered in refractory cases
• ECMO - bridge to definitive therapy in refractory cardiac arrest or severe RV failure

STEP 8 - SUPPORTIVE CARE

• Cautious IV fluid challenge (250-500 mL NS) - RV is preload-dependent but over-loading worsens septal shift and paradoxical motion
• If vasopressors needed: Norepinephrine is preferred for systemic support; maintain MAP >65
• Vasopressin as adjunct to reduce RV afterload while maintaining systemic pressure
• Avoid hypotension during intubation if it becomes necessary

• Minimize intubation if possible - mechanical ventilation causes additional RV afterload
• If intubation required: low TV (6 mL/kg), low PEEP, avoid hypercapnia (worsens pulmonary vasoconstriction)
• Consider prone positioning for refractory hypoxia

• Pleuritic chest pain: consider low-dose opioid or ketorolac
• Avoid excessive sedation

STEP 9 - DOCUMENTATION AND CONSULTATION

• Pulmonology / Respirology - ongoing management
• Cardiology - RV dysfunction management, echo guidance
• Hematology - if underlying thrombophilia suspected
• Vascular surgery / Cardiothoracic surgery - if surgical embolectomy may be needed
• ICU/HDU admission for intermediate-risk (elevated biomarkers + RV dysfunction) or high-risk PE

STEP 10 - LONG-TERM ANTICOAGULATION PLANNING (Start Thinking Now)

• Minimum 3 months anticoagulation for provoked PE
• 6 months to indefinite for unprovoked PE or recurrent VTE
• DOACs (rivaroxaban, apixaban, dabigatran, edoxaban) are preferred for long-term therapy after initial parenteral phase
• Screen for underlying cause: malignancy (CT chest/abdomen/pelvis), thrombophilia panel (ideally off anticoagulation), antiphospholipid syndrome

Quick Reference Summary

PTE Confirmed →
  ↓
Risk-stratify: High / Intermediate / Low
  ↓
Hemodynamically STABLE? → UFH now (80 U/kg bolus + 18 U/kg/hr) 
  → Monitor q15 min for deterioration
  ↓
Hemodynamic instability develops?
  → Check thrombolysis contraindications
  → Stop UFH
  → Alteplase 100mg over 2h IV
  → Restart UFH (no bolus) when aPTT <80s
  ↓
Thrombolysis fails or contraindicated?
  → Catheter-directed therapy / Surgical embolectomy / ECMO

Monitoring UFH with ACT + aPTT - How to Proceed Practically

Understanding What Each Test Tells You

Henry's Clinical Diagnosis (Laboratory Methods): "A variety of laboratory methods can be used to measure UFH. These include APTT, anti-factor Xa activity, activated clotting time (ACT), and protamine reversal. For patients receiving heparin for the treatment of VTE... APTT is the most commonly used assay." ACT is used when APTT performs suboptimally (e.g. very high heparin doses in cardiac bypass) but is equally practical as a POC guide for VTE anticoagulation monitoring.

Step-by-Step Protocol Using ACT + aPTT

1. Baseline Before Heparin

• Get a baseline ACT (normal whole blood ACT: ~70-120 seconds depending on machine/method - get your institution's reference range)
• Get a baseline aPTT (normal ~25-35 sec; records if patient has pre-existing coagulopathy)
• This is mandatory - ACT is meaningless without a pre-heparin baseline

2. Start UFH (as before)

• Bolus: 80 units/kg IV (or 30 units/kg if your institution uses PE-specific protocol)
• Infusion: 18 units/kg/hr continuous IV

3. ACT Monitoring (6-hourly)

• 150 - 200 seconds (approximately 1.5-2.5x baseline/normal)
• Some sources use 180-250 seconds depending on ACT method (kaolin vs celite)

Know your machine: Kaolin-activated ACT (e.g., Hemochron) and celite-ACT give different absolute values for the same heparin level. Your institution's own normal reference range + 1.5-2.5x multiplier is the correct target.

• Check ACT at 6h post-start, then every 6h for first 24h, then every 12h once stable
• After each infusion rate change, recheck ACT in 4-6 hours

4. Once-Daily aPTT - How to Use It

• 1.5 to 2.5 times the upper limit of your lab's normal reference range
• Example: if your lab's normal aPTT = 30 seconds, target = 45-75 seconds
• Many labs report a therapeutic range directly (commonly 60-100 seconds); use that

ISTH Guidance: "Achieving a therapeutic aPTT within the first 24 hours has been confirmed as critical. Failure to achieve therapeutic aPTT within 24h is associated with a statistically significant and clinically important increase in recurrent thromboembolism."

5. The Relationship Between ACT and aPTT

• ACT in range but aPTT subtherapeutic → Commonest discrepancy; often due to elevated Factor VIII (acute phase reactant, common in PE/thrombosis/inflammatory states) falsely shortening aPTT. In this case, trust the ACT - do not over-dose heparin chasing aPTT
• aPTT elevated but ACT normal → Check if lupus anticoagulant present (prolongs aPTT independently of heparin); trust ACT
• Both supratherapeutic → Reduce infusion
• Heparin resistance defined as: needing >35,000 units/day with subtherapeutic aPTT despite adequate ACT - causes include antithrombin deficiency, massive clot burden (PF4 release), elevated factor VIII, or obesity

6. Practical Timing Chart for Your Case

TIME        ACTION
Hour 0      Baseline ACT + aPTT → Give heparin bolus → Start infusion
Hour 6      ACT check → Adjust infusion rate if needed
Hour 12     ACT check → Adjust if needed
Hour 18     ACT check → Adjust if needed
Hour 24     ACT + aPTT (once-daily aPTT) → Confirm therapeutic; adjust if discrepant
Day 2+      ACT q6h (or q12h once stable) + aPTT once daily in morning

7. Special Situations in Your PTE Patient

• If hemodynamic deterioration occurs and you need to thrombolyse: Stop UFH immediately. ACT will normalize in ~60-90 minutes. Give alteplase. Restart UFH (no bolus) when ACT <150 or aPTT <80 sec (2-4 hours post-alteplase).
• If patient has elevated baseline aPTT (lupus anticoagulant, factor deficiency): Rely primarily on ACT for monitoring; aPTT is unreliable in this setting.
• If ACT machine not available overnight: Use aPTT at 6h as a substitute; this is less ideal but acceptable.
• Suspected HIT (platelets drop >50% on day 5-10): Check platelets daily from day 4 onwards with each CBC. If HIT suspected, stop UFH immediately regardless of ACT/aPTT values and switch to a non-heparin anticoagulant (argatroban, fondaparinux).

Summary in One Line